Clopidogrel teva

Clopidogrel teva Bisulfate is a potent oral antiplatelet agent often used in the treatment of coronary artery disease, peripheral vascular disease, and cerebrovascular disease. It works by blocking a receptor called P2Y12. It is also used, along with aspirin, for the prevention of thromboembolism after placement of intra-coronary stent, PTCA and other invasive operations in the cardiovascular system.
Clopidogrel Bisulfate is marketed by Bristol-Myers Squibb and Sanofi-Aventis under the brand name Plavix and considered to be blockbuster. Plavix tablets contain 97.875 mg of Clopidogrel Bisulfate which is the molar equivalent of 75 mg of Clopidogrel base.
Platelet aggregation is important in haemostasis (Blood Products Plasma Expanders and Haemostatics) and is also involved in thrombus formation, particularly in the arterial circulation. Anti-platelet drugs reduce platelet aggregation and are used to prevent further thromboembolic events in patients who have suffered myocardial infarction, ischaemic stroke or transient ischaemic attacks, or unstable angina, and for primary prevention of a thromboembolic event in patients at risk. Some are also used for the prevention of reocclusion or restenosis following angioplasty and bypass procedures. Anti-platelet drugs act through a wide range of mechanisms.